Zhejiang Zhenyuan: It is expected that in the first half of 2026, the company will transition from profit to loss, with a net loss of 11 million to 16 million yuan.

Zhejiang Zhenyuan Announcement: It is expected that the net profit attributable to shareholders of the listed company in the first half of 2026 will be a loss of 11-16 million yuan, a decrease of 119.55% to 128.44% compared to the same period last year, which was 56.26 million yuan. After deducting non-recurring gains and losses, the net profit is expected to be a loss of 18-23 million yuan, a decrease of 159.77% to 176.37% compared to the same period last year, which was 30.1173 million yuan. The reasons for the performance change are as follows: Zhenyuan Bio project has a high investment intensity and high production costs; traditional sectors are affected by pharmaceutical centralized procurement, medical insurance cost control, intensified industry competition, resulting in a decrease in sales revenue and gross profit; self-inspection and payment of taxes and late fees; continued investment in project construction leading to increased financial expenses.